Alliancebernstein L.P. maintained its position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,410 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alliancebernstein L.P. owned about 0.13% of Intra-Cellular Therapies worth $900,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Nine Chapters Capital Management LLC purchased a new position in shares of Intra-Cellular Therapies during the first quarter valued at about $166,000. Highbridge Capital Management LLC purchased a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at about $166,000. American International Group Inc. boosted its position in shares of Intra-Cellular Therapies by 7.1% in the first quarter. American International Group Inc. now owns 21,130 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 1,396 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Intra-Cellular Therapies during the first quarter valued at about $384,000. Finally, Franklin Street Advisors Inc. NC boosted its position in shares of Intra-Cellular Therapies by 135.6% in the first quarter. Franklin Street Advisors Inc. NC now owns 26,060 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 15,000 shares in the last quarter. 66.60% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Intra-Cellular Therapies Inc. (ITCI) opened at 11.01 on Friday. The company’s market cap is $478.10 million. Intra-Cellular Therapies Inc. has a 12-month low of $7.85 and a 12-month high of $45.20. The company has a 50-day moving average of $11.97 and a 200 day moving average of $12.55.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.33. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.03 million. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. Intra-Cellular Therapies’s quarterly revenue was down 52.2% on a year-over-year basis. During the same period last year, the business earned ($0.71) earnings per share. On average, equities research analysts expect that Intra-Cellular Therapies Inc. will post ($2.65) EPS for the current year.
Several research analysts have recently issued reports on the stock. BidaskClub cut shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Piper Jaffray Companies set a $10.00 target price on shares of Intra-Cellular Therapies and gave the stock a “hold” rating in a report on Thursday. Cantor Fitzgerald restated a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, May 16th. Finally, Leerink Swann cut shares of Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating and cut their price target for the company from $29.00 to $10.00 in a report on Tuesday, May 2nd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $24.14.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.